Evidence map›Paper›PMID 22886510›Full record

ArticleRheumatology international2013

The sensitivity, specificity and accuracy of anti-citrulline antibody test in diagnosis of rheumatoid arthritis.

Shahla Abolghasemi, Ashkan Gitipour, Afsaneh Morteza

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Shahla AbolghasemiDepartment of Rheumatology, Azad University of Medicine, Tehran, Iran. swt_f@yahoo.com
Ashkan Gitipour
Afsaneh Morteza

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Citrulline antibody, nowadays, is a new item which has been the center of attention due to its much more specificity to diagnose RA. The aim of the present study was to evaluate the efficacy and accuracy of anti-citrulline antibody test in RA diagnosis among hospitalized patients in Iran. Through a case-control study, we tried to calculate the accuracy of anti-cyclic citrullinated peptide antibody (anti-CCP) test used in the diagnosis of RA enrolling 200 participants divided into two groups of the patients with RA, on the one hand, and other diseases, on the other. Anti-CCP was measured by ELISA technique through which titers more than 15 were defined as high titer. Of all the studied population, 81 (81 %) were in active phase of RA, which had anti-CCP >15 U/ml, while only 25 controls (25 %) experienced these levels. The average anti-CCP was 144 U/ml in cases and 16.05 U/ml in controls with a P value <0.001, which confirmed significant difference between the two. Considering different comments on this matter besides our findings in the present research, we offer a combination of anti-citrulline antibody test rather than anti-CCP and RF to get the best results in RA diagnosis, discrimination and prognosis because of 97 % specificity.

Indexed as

AdultArthritis, RheumatoidAutoantibodiesCase-Control StudiesFemaleHumansMalePeptides, CyclicRheumatoid FactorSensitivity and SpecificityAutoantibodiescyclic citrullinated peptidePeptides, CyclicRheumatoid Factor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.